These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32405630)

  • 1. Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse Effect.
    Saif MW; Romano A; Smith MH; Patel R; Relias V
    Cancer Med J; 2020; 3(2):75-84. PubMed ID: 32405630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study.
    Lamarca A; McCallum L; Nuttall C; Barriuso J; Backen A; Frizziero M; Leon R; Mansoor W; McNamara MG; Hubner RA; Valle JW
    Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):723-731. PubMed ID: 29923433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study.
    Paulson S; Ray D; Aranha S; Scales A; Wang Y; Liu E
    Oncol Ther; 2022 Dec; 10(2):463-479. PubMed ID: 36136274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review.
    Whitcomb DC; Buchner AM; Forsmark CE
    Gastroenterology; 2023 Nov; 165(5):1292-1301. PubMed ID: 37737818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
    Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
    Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exocrine pancreatic insufficiency following esophagectomy.
    Huddy JR; Macharg FM; Lawn AM; Preston SR
    Dis Esophagus; 2013 Aug; 26(6):594-7. PubMed ID: 23199208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Saif MW; Fu J; Smith MH; Weinstein B; Relias V; Daly KP
    J Pancreat Cancer; 2018; 4(1):64-71. PubMed ID: 30788459
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan.
    Chen JS; Bai LY; Cheng HH; Chan SL; Zou JY; Shi X; Houchard A; Truong-Thanh XM; Chen MH
    Oncol Ther; 2024 Aug; ():. PubMed ID: 39215958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET).
    Ström T; Kozlovacki G; Myrenfors P; Almquist M
    Patient Prefer Adherence; 2019; 13():1799-1807. PubMed ID: 31695341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs.
    Rinzivillo M; De Felice I; Magi L; Annibale B; Panzuto F
    Pancreatology; 2020 Jul; 20(5):875-879. PubMed ID: 32684368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exocrine pancreatic insufficiency after bariatric surgery: a bariatric surgery center of excellence experience.
    Moore HN; Chirco AR; Plescia T; Ahmed S; Jachniewicz B; Rajasekar G; Ali MR; Lyo V
    Surg Endosc; 2023 Feb; 37(2):1466-1475. PubMed ID: 35768735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiproliferative Effect of Somatostatin Analogs -  Data Analyses and Clinical Applications in the Context of the CLARINET Study].
    Bencsiková B
    Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.
    Khan MS; Walter T; Buchanan-Hughes A; Worthington E; Keeber L; Feuilly M; Grande E
    World J Gastroenterol; 2020 Aug; 26(30):4537-4556. PubMed ID: 32874063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Saif MW
    Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
    Harrow B; Fagnani F; Nevoret C; Truong-Thanh XM; de Zélicourt M; de Mestier L
    Adv Ther; 2022 Apr; 39(4):1754-1771. PubMed ID: 35190997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
    Massironi S; Conte D; Rossi RE
    Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study.
    Chicharro P; Paniagua A; Rodríguez-Jiménez P; Ibañes S; Cortina B; Riveiro J; Sampedro-Núñez MÁ; Fraga J; Marazuela M; Daudén E
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1887-1892. PubMed ID: 29377286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
    Enzler T; Fojo T
    Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
    Faggiano A
    J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.